Incyte | INCY - Interest Income


Incyte reported $33.69M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.33M 86K Dec/2025
Agios Pharmaceuticals USD 12.41M 959K Dec/2025
Alnylam Pharmaceuticals USD 26.63M 2.05M Dec/2025
BioCryst Pharmaceuticals USD -0.13 3.59M Dec/2024
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Eli Lilly USD 65M 25M Sep/2025
Exelixis USD 16.13M 1.3M Mar/2026
Gilead Sciences USD 95M 7M Dec/2025
Incyte USD 33.69M 2.93M Mar/2026
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
MacroGenics USD 1.53M 114K Sep/2025
Merck USD 69M 27M Dec/2025
Moderna USD 70M 3M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD 115M 51M Mar/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 193.3M 18.2M Dec/2025
Sarepta Therapeutics USD 8.74M 359K Dec/2025
Ultragenyx Pharmaceutical USD 6.51M 649K Dec/2025
Vertex Pharmaceuticals USD 114.8M 7.1M Mar/2026